Triple-Negative Myelofibrosis: Disease Features, Response to Treatment and Outcomes

CONCLUSION: TN-MF is invariably associated with significantly decreased survival and more aggressive clinical behavior with higher rates of leukemic transformation and shorter duration of response to ruxolitinib. Mutations impacting RNA splicing, epigenetic modification and signaling (SRSF2, SETBP1, IDH2, CBL, and GNAS) are more common in TN-MF, which likely drive its aggressive course and may account for suboptimal responses to JAK inhibition.PMID:38548563 | DOI:10.1016/j.clml.2024.03.001

Source: Clinical Lymphoma and Myeloma - March 28, 2024 Category: Cancer & Oncology Authors: Luis E Aguirre Akriti Jain Somedeb Ball Najla Al Ali Virginia O Volpe Sara Tinsley-Vance David Sallman Kendra Sweet Jeffrey Lancet Eric Padron Seongseok Yun Andrew Kuykendall Rami Komrokji Source Type: research